# Amgen sells tarlatamab in its home market under the name Imdelltra.

*biotech · news · 2026-04-10 · Reuters*

## Key points

- Tarlatamab is a targeted immunotherapy for extensive-stage small cell lung cancer post-chemotherapy.
- Amgen markets tarlatamab as Imdelltra in the United States.
- Tarlatamab is a bispecific antibody that links cancer cells and immune cells for targeted killing.
- Analysts estimate tarlatamab could generate over $2 billion in annual sales for Amgen.

**Companies:** Amgen
**Countries:** United States, China, Hong Kong

[Read the full story on Reuters](https://www.reuters.com/legal/litigation/amgens-lung-cancer-drug-tarlatamab-wins-china-approval-2026-04-10/)

---

Canonical: https://newsio.io/n/d1950a6d-23e9-4680-a3b2-47e72e593394/amgen-sells-tarlatamab-in-its-home-market-under-the-name-imdelltra
Summarized by Newsio from Reuters. https://newsio.io/how-it-works